Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
D. Ross Camidge(University of Colorado Denver), Liza C. Villaruz(University of Pittsburgh Medical Center), Yiyun Tang(Southwest University), Sherry Chia-E Wang(Pfizer (United States)), Keith D. Wilner(Pfizer (United States)), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Steven Ades(University of Vermont Medical Center), Umberto Conte(Pfizer (United States)), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Danielle Murphy(Pfizer (United States)), Jared Weiss(University of North Carolina at Chapel Hill)
Cited by 80
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k